Oral Biologics Market Growth, Trends and Forecast to 2028 – Global Analysis By Delivery (Video, Voice, Text, and Hybrid), By Deployment (Cloud and On-Premise), By Model (Gamification, Big Data, Virtual Learning Model, and Others), By Focus (Mathematics, Literature, Finance & Marketing, and Others), By Application (Educational Institutes, Corporate, and Online Course Providers) and By Geography

MARKET DEFINITION

Oral biologics is the application of biotechnology to medicine. They are produced from cell lines and are large portentous molecules such as recombinant proteins, peptides, and vaccines for a range of conditions, such as diabetes, inflammatory diseases (rheumatoid arthritis and inflammatory bowel disease [IBD]), cancer, and others.  The most convenient and preferred form of drug administration is oral administration. Contrary to injection, oral administration of insulin has additional advantages. For instance, it more nearly resembles the physiology of endogenous insulin generated by the pancreas, which results in lower levels of systemic insulin and fewer hypoglycemic episodes and weight gain issues. Insulin is taken orally also lessens the risk of developing a needle-related infection.

MARKET DYNAMICS

The growing prevalence of chronic diseases such as cancer, asthma, and arthritis is one of the major drivers of the market. In addition, biologics further stimulate the immune system's attack on cancer cells, aiding the body's natural defenses in getting rid of the disease-causing cells. According to a United Nations publication, by 2030, chronic diseases are predicted to account for 70% of all fatalities worldwide. About 60% of the world's population is predicted to be affected by chronic disease. The International Diabetes Federation (2021) estimated that 2021 million people worldwide had diabetes, and that figure would rise to 642 million by the year 2030. Furthermore, key players in the market are investing in developing innovative products and solutions which is anticipated to create lucrative opportunities. For instance, Insulin Tregopil, a first-in-class oral, prandial insulin, is being developed by Biocon Limited and is currently conducting phase II/III clinical trials for the treatment of patients with type 2 diabetes.

REPORT SCOPE  

The report titled “Global Oral Biologics Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Oral Biologics market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Oral Biologics market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Oral Biologics Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW  

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

MARKET SEGMENTATION  

The Global Oral Biologics Market is segmented based on drug class, disease indication, distribution channel, and region. Based on drug class, the market has been segmented into Glucagon-like Peptide 1 (GLP-1) Receptor Agonist, Hormone, Recombinant Enzyme, Guanylate Cyclase-C Agonist, Somatostatin Analogue, and Others, whereas based on Disease Indication, the market comprises Diabetes, Hyperoxaluria, Acromegaly, Irritable Bowel Syndrome (IBS), Chronic Idiopathic Constipation (CIC), and Inflammatory Bowel Disease (IBD)m Hypoparathyroidism, and Others. Based on distribution channel, the market has been segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others.

COMPETITION LANDSCAPE  

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Oral Biologics market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Oral Biologics market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Oral Biologics market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Oral Biologics industry in the past three years.

Key players in the Global Oral Biologics Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

• Novo Nordisk A/S
• Biocon Limited
• Oramed Pharmaceuticals, Inc.
• Rani Therapeutics
• Entera Bio Ltd.
• AbbVie Inc.
• Enteris BioPharma, Inc.
• Chiasma, Inc.
• Allena Pharmaceuticals, Inc.
• Concord Biotech
• Aurobindo Pharma Ltd.
• Lundbeck A/S
• Sanofi-Aventis
• Roche

COVID-19 IMPACT ANALYSIS ON THE GLOBAL ORAL BIOLOGICS MARKET  

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED  

1. What is the current size of the global Oral Biologics market?
2. What will be the growth rate of the market over the forecast period?
3. Who are the key manufacturers/vendors in the Oral Biologics market space?
4. What are the major market opportunities and market risks faced by the market?
5. What is the impact of COVID-19 on the market?
6. What are the revenue, sales, and price analysis of the top manufacturers in this market?
7. What are the key outcomes of Porter's five forces model?
8. Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:  

• The report offers comprehensive data on the Oral Biologics market elaborating on the current state and future growth prospects both globally and regionally
• It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth
• The report offers deep-dive insights into each market segment and critical factors responsible for its growth
• The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position
• The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions
• Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope
• The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

Chapter 1. Executive Summary
1.1. Market Outlook
1.2. Market Segment Outlook
1.3. Geography Outlook
1.4. Absolute $ Opportunity

Chapter 2. Research Methodology
2.1. Research Approach
2.2. Scope, Definition, and Assumptions
2.3. Data Sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary Data Mining
2.3.2. Primary Sources
2.3.2.1. Statistical Distribution Channel
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective

Chapter 3. Market Outlook
3.1. Introduction
3.2. Key Trends
3.2.1. Drug Class Trends
3.2.2. Disease Indication Trends
3.2.3. Distribution Channel Trends
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Impact Analysis of Market Drivers
3.3.2. Market Restraints
3.3.2.1. Impact Analysis of Market Restraints
3.3.3. Market Opportunities
3.3.3.1. Impact Analysis of Market Opportunities
3.3.4. Market Challenges
3.3.4.1. Impact Analysis of Market Challenges
3.4. Porter’s Five Forces’ Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrant
3.4.4. Threat of Substitutes
3.4.5. Competitive Rivalry
3.5. Value Chain Analysis: Global Oral Biologics Market
3.6. COVID-19 Impact Assessment in Oral Biologics Market
3.6.1. Impact Assessment on Global Oral Biologics Market
3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4. Global Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
4.1. Global Oral Biologics Market Share, By Drug Class, 2017 - 2028 (USD Million)
4.1.1. Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
4.1.2. Hormone
4.1.3. Recombinant Enzyme
4.1.4. Guanylate Cyclase-C Agonist
4.1.5. Somatostatin Analogue
4.1.6. Others

Chapter 5. Global Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
5.1. Global Oral Biologics Market Share, By Disease Indication, 2017 - 2028 (USD Million)
5.1.1. Diabetes
5.1.2. Hyperoxaluria
5.1.3. Acromegaly
5.1.4. Irritable Bowel Syndrome [IBS]
5.1.5. Chronic Idiopathic Constipation [CIC]
5.1.6. Others (Inflammatory Bowel Disease [IBD], Hypoparathyroidism, and Others)

Chapter 6. Global Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
6.1. Global Oral Biologics Market Share, By Distribution Channel, 2017 - 2028 (USD Million)
6.1.1. Hospital Pharmacies
6.1.2. Retail Pharmacies
6.1.3. Online Pharmacies
6.1.4. Others

Chapter 7. Global Oral Biologics Market Overview, By Geography, 2017 - 2028 (USD Million)
7.1. Global Oral Biologics Market Share, By Geography, 2017 - 2028 (USD Million)
7.1.1. Market Disease Indication and Projections, by Countries, 2017 - 2028 (USD Million)
7.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 8. North America Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
8.1. North America Oral Biologics Market Overview, 2017 - 2028 (USD Million)
8.1.1. Market Disease Indication and projections, 2017 - 2028 (USD Million)
8.1.2. North America Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.1.3. North America Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
8.1.4. North America Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2. North America Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
8.2.1. U.S. Oral Biologics Market Overview, 2017 - 2028 (USD Million)
8.2.1.1. U.S. Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.1.2. U.S. Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
8.2.1.3. U.S. Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.2. Canada Oral Biologics Market Overview, 2017 - 2028 (USD Million)
8.2.2.1. Canada Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.2.2. Canada Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
8.2.2.3. Canada Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
8.2.3. Mexico Oral Biologics Market Overview, 2017 - 2028 (USD Million)
8.2.3.1. Mexico Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
8.2.3.2. Mexico Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
8.2.3.3. Mexico Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 9. Europe Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
9.1. Europe Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.1.1. Market Disease Indication and projections, 2017 - 2028 (USD Million)
9.1.2. Europe Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.1.3. Europe Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.1.4. Europe Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2. Europe Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
9.2.1. Germany Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.2.1.1. Germany Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.1.2. Germany Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.2.1.3. Germany Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.2. France Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.2.2.1. France Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.2.2. France Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.2.2.3. France Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.3. UK Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.2.3.1. UK Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.3.2. UK Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.2.3.3. UK Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.4. Italy Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.2.4.1. Italy Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.4.2. Italy Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.2.4.3. Italy Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.5. Spain Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.2.5.1. Spain Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.5.2. Spain Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.2.5.3. Spain Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.6. NORDIC Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.2.6.1. NORDIC Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.6.2. NORDIC Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.2.6.3. NORDIC Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.7. Russia and CIS Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.2.7.1. Russia and CIS Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.7.2. Russia and CIS Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.2.7.3. Russia and CIS Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
9.2.8. Rest of Europe Oral Biologics Market Overview, 2017 - 2028 (USD Million)
9.2.8.1. Rest of Europe Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
9.2.8.2. Rest of Europe Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
9.2.8.3. Rest of Europe Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 10. Asia Pacific Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
10.1. Asia Pacific Oral Biologics Market Overview, 2017 - 2028 (USD Million)
10.1.1. Market Disease Indication and projections, 2017 - 2028 (USD Million)
10.1.2. Asia Pacific Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.1.3. Asia Pacific Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
10.1.4. Asia Pacific Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2. Asia Pacific Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
10.2.1. India Oral Biologics Market Overview, 2017 - 2028 (USD Million)
10.2.1.1. India Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.1.2. India Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
10.2.1.3. India Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.2. China Oral Biologics Market Overview, 2017 - 2028 (USD Million)
10.2.2.1. China Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.2.2. China Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
10.2.2.3. China Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.3. Japan Oral Biologics Market Overview, 2017 - 2028 (USD Million)
10.2.3.1. Japan Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.3.2. Japan Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
10.2.3.3. Japan Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.4. ASEAN Oral Biologics Market Overview, 2017 - 2028 (USD Million)
10.2.4.1. ASEAN Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.4.2. ASEAN Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
10.2.4.3. ASEAN Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.5. South Korea Oral Biologics Market Overview, 2017 - 2028 (USD Million)
10.2.5.1. South Korea Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.5.2. South Korea Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
10.2.5.3. South Korea Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.6. Australia Oral Biologics Market Overview, 2017 - 2028 (USD Million)
10.2.6.1. Australia Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.6.2. Australia Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
10.2.6.3. Australia Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
10.2.7. Rest of Asia Pacific Oral Biologics Market Overview, 2017 - 2028 (USD Million)
10.2.7.1. Rest of Asia Pacific Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
10.2.7.2. Rest of Asia Pacific Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
10.2.7.3. Rest of Asia Pacific Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 11. South America Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
11.1. South America Oral Biologics Market Overview, 2017 - 2028 (USD Million)
11.1.1. Market Disease Indication and projections, 2017 - 2028 (USD Million)
11.1.2. South America Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.1.3. South America Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
11.1.4. South America Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2. South America Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
11.2.1. Brazil Oral Biologics Market Overview, 2017 - 2028 (USD Million)
11.2.1.1. Brazil Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.1.2. Brazil Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
11.2.1.3. Brazil Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.2. Argentina Oral Biologics Market Overview, 2017 - 2028 (USD Million)
11.2.2.1. Argentina Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.2.2. Argentina Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
11.2.2.3. Argentina Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
11.2.3. Rest of South America Oral Biologics Market Overview, 2017 - 2028 (USD Million)
11.2.3.1. Rest of South America Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
11.2.3.2. Rest of South America Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
11.2.3.3. Rest of South America Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 12. Middle East & Africa Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
12.1. Middle East & Africa Oral Biologics Market Overview, 2017 - 2028 (USD Million)
12.1.1. Market Disease Indication and projections, 2017 - 2028 (USD Million)
12.1.2. Middle East & Africa Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.1.3. Middle East & Africa Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
12.1.4. Middle East & Africa Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2. Middle East & Africa Oral Biologics Market Overview, By Countries, 2017 - 2028 (USD Million)
12.2.1. GCC Oral Biologics Market Overview, 2017 - 2028 (USD Million)
12.2.1.1. GCC Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.1.2. GCC Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
12.2.1.3. GCC Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.2. South Africa Oral Biologics Market Overview, 2017 - 2028 (USD Million)
12.2.2.1. South Africa Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.2.2. South Africa Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
12.2.2.3. South Africa Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)
12.2.3. Rest of Middle East & Africa Oral Biologics Market Overview, 2017 - 2028 (USD Million)
12.2.3.1. Rest of Middle East & Africa Oral Biologics Market Overview, By Drug Class, 2017 - 2028 (USD Million)
12.2.3.2. Rest of Middle East & Africa Oral Biologics Market Overview, By Disease Indication, 2017 - 2028 (USD Million)
12.2.3.3. Rest of Middle East & Africa Oral Biologics Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 13. Competitive Landscape
13.1. Competitive Environment, 2021
13.2. Strategic Framework
13.2.1. Partnership/Collaborations/Agreement
13.2.2. Expansion
13.2.3. Mergers & Acquisitions
13.2.4. New Product Development

Chapter 14. Key Vendor Analysis
14.1. Novo Nordisk A/S
14.1.1. Business Overview
14.1.2. Product Benchmarking
14.1.3. Financial Data
14.1.4. Strategic Overview
14.1.5. Key Developments
14.1.6. SWOT Analysis
14.2. Biocon Limited
14.2.1. Business Overview
14.2.2. Product Benchmarking
14.2.3. Financial Data
14.2.4. Strategic Overview
14.2.5. Key Developments
14.2.6. SWOT Analysis
14.3. Oramed Pharmaceuticals, Inc.
14.3.1. Business Overview
14.3.2. Product Benchmarking
14.3.3. Financial Data
14.3.4. Strategic Overview
14.3.5. Key Developments
14.3.6. SWOT Analysis
14.4. Rani Therapeutics
14.4.1. Business Overview
14.4.2. Product Benchmarking
14.4.3. Financial Data
14.4.4. Strategic Overview
14.4.5. Key Developments
14.4.6. SWOT Analysis
14.5. Entera Bio Ltd.
14.5.1. Business Overview
14.5.2. Product Benchmarking
14.5.3. Financial Data
14.5.4. Strategic Overview
14.5.5. Key Developments
14.5.6. SWOT Analysis
14.6. AbbVie Inc.
14.6.1. Business Overview
14.6.2. Product Benchmarking
14.6.3. Financial Data
14.6.4. Strategic Overview
14.6.5. Key Developments
14.6.6. SWOT Analysis
14.7. Enteris BioPharma, Inc.
14.7.1. Business Overview
14.7.2. Product Benchmarking
14.7.3. Financial Data
14.7.4. Strategic Overview
14.7.5. Key Developments
14.7.6. SWOT Analysis
14.8. Chiasma, Inc.
14.8.1. Business Overview
14.8.2. Product Benchmarking
14.8.3. Financial Data
14.8.4. Strategic Overview
14.8.5. Key Developments
14.8.6. SWOT Analysis
14.9. Allena Pharmaceuticals, Inc.
14.9.1. Business Overview
14.9.2. Product Benchmarking
14.9.3. Financial Data
14.9.4. Strategic Overview
14.9.5. Key Developments
14.9.6. SWOT Analysis
14.10. Concord Biotech
14.10.1. Business Overview
14.10.2. Product Benchmarking
14.10.3. Financial Data
14.10.4. Strategic Overview
14.10.5. Key Developments
14.10.6. SWOT Analysis
14.11. Aurobindo Pharma Ltd.
14.11.1. Business Overview
14.11.2. Product Benchmarking
14.11.3. Financial Data
14.11.4. Strategic Overview
14.11.5. Key Developments
14.11.6. SWOT Analysis
14.12. H. Lundbeck A/S
14.12.1. Business Overview
14.12.2. Product Benchmarking
14.12.3. Financial Data
14.12.4. Strategic Overview
14.12.5. Key Developments
14.12.6. SWOT Analysis
14.13. Sanofi-Aventis
14.13.1. Business Overview
14.13.2. Product Benchmarking
14.13.3. Financial Data
14.13.4. Strategic Overview
14.13.5. Key Developments
14.13.6. SWOT Analysis
14.14. Roche
14.14.1. Business Overview
14.14.2. Product Benchmarking
14.14.3. Financial Data
14.14.4. Strategic Overview
14.14.5. Key Developments
14.14.6. SWOT Analysis

Chapter 15. Future Outlook of the Market
Disclaimer